Skip to content

Effect of Wuda Granule on Enhanced Recovery After Surgery (ERAS) for Gastrointestinal Function Following Laparoscopic Liver Resection in Liver Cancer: A Randomized Double-Blind Controlled Trial

Effect of Wuda Granule on Enhanced Recovery After Surgery (ERAS) for Gastrointestinal Function Following Laparoscopic Liver Resection in Liver Cancer: A Randomized Double-Blind Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001960
Enrollment
Unknown
Registered
2025-10-22
Start date
2025-10-31
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative gastrointestinal dysfunction

Interventions

Wuda Granule Treatment Group:Wuda Granule (10 g/bag), provided by the Preparation Room of Guangdong Provincial Hospital of Chinese Medicine. Drug composition: Amomi Fructus, Linderae Radix, Ginseng Ra
Placebo Control Group:Placebo Granules (10 g/bag), provided by the Preparation Room of Guangdong Provincial Hospital of Chinese Medicine, mainly consist of liquid caramel, dextrin, and a bittering age

Sponsors

Department of Hepatobiliary Surgery Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 80 years (inclusive) 2.Diagnosed with liver cancer and scheduled for laparoscopic liver resection 3.Operative time = 4 hours 4.Liver resection extent < 50% 5.Child-Pugh Class A liver function 6.Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score 0-1 7.Signed informed consent obtained

Exclusion criteria

Exclusion criteria: 1.Patients with concurrent portal hypertension 2.Patients with concurrent portal vein tumor thrombus (PVTT) 3.Combined resection of other organs besides gallbladder 4.Intraoperative blood loss > 800 ml 5.Receipt of preoperative conversion therapy 6.History of prior abdominal surgery 7.Diagnosis of psychiatric disorders 8.Pregnancy or lactation 9.Allergy to investigational drugs 10.Patients who are currently participating or have participated in other clinical trials within 1 month prior to enrollment in this study. 11.Patients deemed by the investigator as unsuitable for participation in this clinical study.

Design outcomes

Primary

MeasureTime frame
Time to First Flatus After Surgery;

Secondary

MeasureTime frame
Corticotropin releasing hormone;Incidence of Postoperative Bowel Obstruction;Clavien-Dindo Classification of Surgical Complications;Time to First Defecation After Surgery;Time to First Oral Diet Tolerance After Surgery;Perioperative Gastrointestinal Symptom Score;Postoperative Length of Stay;Bowel Sound Recovery Time;Ghrelin;Intake Feeling nauseated Emesis Exam and Duration of symptoms scoring systemIntake Feeling nauseated Emesis Exam and Duration of symptoms scoring system;Superoxide Dismutase;Tumor Necrosis Factor;Identity-Consequence Fatigue Scale;Visual Analogue Scale;Malondialdehyde;Interleukin-6;Qi Deficiency and Qi Stagnation Syndrome Scale;

Countries

China

Contacts

Public ContactJunming He

Guangdong Provincial Hospital of Chinese Medicine

hejunming0101@sina.com13501538271

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026